SCYX Company Profile and Key Details

Q: Who are the executives of SCYX?

Mr. Ivor Macleod CPA, M.B.A.Chief Financial OfficerDr. Marco Taglietti M.D.Chief Executive Officer, Pres & DirectorMs. Christine R. Coyne M.B.A.Chief Commercial OfficerMr. David Gonzalez Angulo M.D.Chief Executive Officer, Pres & DirectorMr. Scott Sukenick J.D.Chief Legal Officer & Corporation Sec.Debbie EtchisonExecutive Director of CommunicationsMs. Daniella GiganteVice President of HR

NASDAQ : SCYX

SCYNEXIS

$0.89

-0.0004-0.05%

At Close 4:00 PM

69.23

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

SCYNEXIS, Inc. (SCYX) stock declined over -0.05%, trading at $0.89 on NASDAQ, down from the previous close of $0.89. The stock opened at $0.88, fluctuating between $0.85 and $0.90 in the recent session.

Stock Snapshot

0.8883

Prev. Close

39.66M

Market Cap

0.85

Day Low

-5.22

P/E Ratio

-0.17

EPS (TTM)

1.62

Cash Flow per Share

0.88

Open

44.66M

Number of Shares

0.9

Day High

89.61%

Free Float in %

1.96

Book Value

258.46K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2026	0.88	0.90	0.85	0.89	258.56K
Apr 01, 2026	0.91	0.91	0.83	0.89	635.75K
Mar 31, 2026	0.80	0.92	0.76	0.92	12.54M
Mar 30, 2026	0.82	0.84	0.78	0.79	81.42K
Mar 27, 2026	0.84	0.84	0.81	0.81	144.44K
Mar 25, 2026	0.90	0.95	0.88	0.88	33.38K
Mar 24, 2026	0.89	0.90	0.87	0.90	120.1K
Mar 23, 2026	0.93	0.95	0.87	0.88	268.72K
Mar 20, 2026	0.91	0.94	0.88	0.93	267.28K
Mar 19, 2026	0.90	0.92	0.88	0.89	85.13K
Mar 18, 2026	0.92	0.92	0.88	0.90	131.96K
Mar 17, 2026	0.92	0.94	0.90	0.92	176.27K
Mar 16, 2026	0.87	0.96	0.86	0.90	417.51K
Mar 13, 2026	0.90	0.91	0.85	0.86	222.69K
Mar 12, 2026	0.89	0.90	0.86	0.89	195.48K
Mar 11, 2026	0.90	0.93	0.86	0.89	305.95K
Mar 10, 2026	0.86	0.93	0.85	0.90	437.31K
Mar 09, 2026	0.82	0.86	0.77	0.86	649.24K
Mar 06, 2026	0.81	0.82	0.73	0.80	934K
Mar 03, 2026	0.76	0.76	0.72	0.75	131.17K

Contact Details

Jersey City, NJ 07302-6548

United States

https://www.scynexis.com 201 884 5485

About Company

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Stock Peers

ITCI

Intra-Cellular Therapies, Inc.$131.87 NBIX

-0.96-0.72%

Neurocrine Biosciences, Inc.$131.60 LNTH

0.4+0.53%

Lantheus Holdings, Inc.$76.10 ANIP

-1.75-2.30%

ANI Pharmaceuticals, Inc.$74.21 PAHC

0.76+1.39%

Phibro Animal Health Corporation$55.52 SUPN

-0.96-1.87%

Supernus Pharmaceuticals, Inc.$50.48 HROW

-0.12-0.34%

Harrow Health, Inc.$35.31 COLL

-0.94-2.83%

Collegium Pharmaceutical, Inc.$32.31 PETQ

-0.01-0.03%

PetIQ, Inc.$30.98 RGC

-2.92-8.66%

Regencell Bioscience Holdings Limited$30.80

Company Overview

The stock is currently mid-range between its 52-week high and low $0.56 and $1.31. With a market capitalization of about $39.66 million, SCYNEXIS, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.32). Key stats such as the average daily volume over the past year has been around 581.05 thousand shares, volume is running light vs its 52-week average. Headquartered in Jersey City, NJ, SCYNEXIS, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO David Gonzalez Angulo, the company employs approximately 28 people and listed since May 02, 2014. SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States.

Technical Performance

SCYX has shown mixed momentum, losing -1.98% over the past week and -14.84% over the past quarter, though year-to-date performance is up 1.61%. Short-term trend indicators are mixed aligned (SMA20 -6.95%, SMA50 0.81%, SMA200 -8.1%). The stock’s 14-day RSI is 44.33 (neutral), while the ATR of 0.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -46.18% below its high and over 24.78% above its low. Average 10-day trading volume of 1.97 million shares is significantly above the 3-month average of 587.36 thousand, indicating heightened recent market interest.

Valuation Metrics

SCYNEXIS, Inc. trades at a P/E ratio of -4.49, slightly below the S&P 500 average, with a price-to-sales ratio of 1.93 and a price-to-book ratio of 0.78 suggesting the stock is closer to book value. The P/FCF stands at -7.51, also below market averages.

Dividend & Fair Value

SCYNEXIS, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.14. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

SCYNEXIS, Inc. generated EPS of -$0.54 over the past year. Five-year average earnings growth is 46.02%. Wall Street analysts project EPS growth of 0.25% annually over the next five years. The latest quarter delivered EPS of -$0.17. The next quarter is forecast at $0.13. Next year's EPS is expected at -$73.83. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $3.00 to $3.00. The high target offers 237.08% upside. The low target suggests 237.08% downside. The mean target is $3.00. This offers 237.08% upside. SCYNEXIS, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 05, 2025, missed forecasts by -19.05%. The prior quarter beat by -39.13%. Over the last six quarters, Apple has recorded several small beats. These include 57.89% in August 08, 2024.

Shareholding & Insider Activity

SCYNEXIS, Inc. has 41.92 million shares outstanding. The public float is 37.57 million shares, elevated short interest at 1.70% of float. This equals 519.39 thousand shares. The short ratio is 2.71 days. Institutional investors hold 28.71% of the float. Insiders own 2.16%. PERCEPTIVE ADVISORS LLC holds 1.80 million shares, Ventech Capital II has 414.21 thousand shares and Nothias Jean-Yves has 295.08 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, SCYNEXIS generated $140.14M in revenue, or $2.90 per share. Gross margin was 88.27%, operating margin 51.85%, and net profit margin 47.84%. Returns are exceptional, with ROA at 52.21% and ROE at 91.88%.
On valuation metrics, SCYNEXIS trades at a P/E of -4.49, P/S of 1.93 and P/B of 0.78. The current ratio is 7.04 and quick ratio is 7.04. Debt-to-equity is 0.04, supported by a cash flow-to-debt ratio of -2.43.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, SCYNEXIS posted revenue of $140.14M, down slightly from $5.09M in the prior quarter. Gross profit was $123.71M (margin 88.27%). Operating income was $72.67M (margin 51.9%). Net income was$67.04M (EPS $1.40).
The company ended the quarter with $74.74M in cash and short-term investments, a total debt of $15.08M, and net debt of - $19.35M. Total assets were $128.41M, with equity of $72.96M. Financials further reflected stability, with operating cash flow of $60.16M, free cash flow of $60.16M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that SCYNEXIS, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.74%, with price expected at $0.93 by April 16, 2026, within a range of $0.87 to $0.99 3-Month Outlook: Projected fall of -35.8%, reaching $0.57 by July 01, 2026, with a range of $0.51 to $0.61. 1-Year Outlook: Projected gain of 830.28%, with price at $8.26 by April 02, 2027, within a range of $4.48 to $9.95.

Key Takeaways

SCYNEXIS, Inc. (NASDAQ:SCYX) shares are flat 1.61% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows SCYNEXIS, Inc. trading at a premium to the broader market with a P/E of -4.49. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.07, suggesting 1259.39% upside. Our AI forecast model points to short-term strength (4.74% over two weeks), a medium-term fall (-35.8% over three months), and a longer-term gain (830.28% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current SCYNEXIS, Inc. (SCYX) stock price?

SCYNEXIS, Inc. (NASDAQ: SCYX) stock price is $0.89 in the last trading session. During the trading session, SCYX stock reached the peak price of $0.90 while $0.85 was the lowest point it dropped to. The percentage change in SCYX stock occurred in the recent session was -0.05% while the dollar amount for the price change in SCYX stock was - $0.00.

SCYX's industry and sector of operation?

The NASDAQ listed SCYX is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. SCYNEXIS, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SCYX?

Mr. Ivor Macleod CPA, M.B.A.
Chief Financial Officer
Dr. Marco Taglietti M.D.
Chief Executive Officer, Pres & Director
Ms. Christine R. Coyne M.B.A.
Chief Commercial Officer
Mr. David Gonzalez Angulo M.D.
Chief Executive Officer, Pres & Director
Mr. Scott Sukenick J.D.
Chief Legal Officer & Corporation Sec.
Debbie Etchison
Executive Director of Communications
Ms. Daniella Gigante
Vice President of HR

How SCYX did perform over past 52-week?

SCYX's closing price is 57.15% higher than its 52-week low of $0.57 where as its distance from 52-week high of $1.31 is -32.22%.

How many employees does SCYX have?

Number of SCYX employees currently stands at 28.

Link for SCYX official website?

Official Website of SCYX is: https://www.scynexis.com

How do I contact SCYX?

SCYX could be contacted at phone 201 884 5485 and can also be accessed through its website. SCYX operates from 1 Evertrust Plaza, Jersey City, NJ 07302-6548, United States.

How many shares of SCYX are traded daily?

SCYX stock volume for the day was 258.46K shares. The average number of SCYX shares traded daily for last 3 months was 581.05K.

What is the market cap of SCYX currently?

The market value of SCYX currently stands at $39.66M with its latest stock price at $0.89 and 44.66M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	28
Beta	1.32
Sales or Revenue	$140.14M
5Y Sales Change%	49.007%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

SCYX Company Profile and Key Details

SCYNEXIS

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Dividend & Fair Value

Valuation Metrics

Company Overview

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways